Shots:

• The Institute for Protein Design will utilize its de novo design technique to expand the versatility of protein-based therapies. Amgen has provided funding for three research projects utilizing IPD’s de novo design technique & optimizing Amgen's repertoire of BiTE Ab
• The focus of the collaboration is to test new technologies & develop protein-based therapies with the goal of expanding the types of tumors targeted by the therapies
• IPD helps Amgen to develop Ab against drug targets and to produce new ways- modulating the activity of the immune system. BiTE (Bispecific T cell engager) technology is an immune-oncology platform- engaging patients' own T cells to tumor-specific antigen- eliminating detectable cancer

Ref: Amgen | Image: Pinterest